There is evolving interest in the use of mesenchymal stem cells (MSC) in solid organ transplantation. Pre-clinical transplantation models show efficacy of MSC in prolonging graft survival and a number of clinical studies are planned or underway. At a recent meeting of the MISOT consortium (MSC In Solid Organ Transplantation) the advances of these studies were evaluated and mechanisms underlying the potential effects of MSC discussed. Continued discussion is required for definition of safety and eventually efficacy endpoints for MSC therapy in solid organ transplantation.

Additional Metadata
Keywords Clinical trial, MISOT, Mesenchymal stem cell, Solid organ transplantation
Persistent URL dx.doi.org/10.1097/TP.0b013e3181ea4240, hdl.handle.net/1765/27295
Journal Transplantation
Citation
Hoogduijn, M.J, Popp, F, Grohnert, A.U, Crop, M.J, van Rhijn, M, Rowshani, A.T, … Dahlke, M.H. (2010). Advancement of mesenchymal stem cell therapy in solid organ transplantation (MISOT). Transplantation, 90(2), 124–126. doi:10.1097/TP.0b013e3181ea4240